Source comparison
The Blunt Truth About TB500 vs TB-500 Naming
Here's the honest answer: the hyphen means nothing. It's a vendor branding artifact that became entrenched in research nomenclature before anyone thought to standardize it. The same peptide is sold under both labels because manufacturers know researchers will
This comparison does not assign a generated winner or score.
- Here's the honest answer: the hyphen means nothing. It's a vendor branding artifact that became entrenched in research nomenclature before anyone thought to standardize it. The same peptide is sold under both labels because manufacturers know researchers will order whichever format they saw cited in the last paper they read. No chemical difference exists. No functional difference exists. No regulatory body cares which you use. The only thing that matters is verifying the amino acid sequence in the COA matches the 43-residue Thymosin Beta-4 structure you need for your experiment. If it does, you have the right peptide. Whether the label says TB500, TB-500, or "magic repair molecule" is irrelevant to your assay's outcome. Stop overthinking the punctuation and start scrutinizing the purity data, endotoxin levels, and storage conditions that actually affect experimental reproducibility. The peptide research field tolerates this naming chaos because function trumps formatting. And that's un
- Peptide quality depends on synthesis precision, not naming conventions. Every batch leaving a reputable facility undergoes HPLC verification, mass spectrometry, and amino acid analysis to confirm the sequence matches the intended target. The designation on the label is the last thing that determines whether your wound healing assay, angiogenesis study, or tissue regeneration protocol succeeds. What determines success is whether the peptide was synthesized correctly, purified to ≥98%, stored at appropriate temperatures, and reconstituted following sterile protocols. A lab that fixates on whether to order TB500 or TB-500 but ignores the COA's purity percentage, endotoxin count, and batch-to-batch variability is optimizing the wrong variable. We've seen researchers delay experiments by weeks debating nomenclature while using peptides stored improperly or reconstituted with non-sterile water. That's where experimental failure occurs, not in the presence or absence of a hyphen.
- If you're sourcing peptides for rigorous biological research, establish vendor qualification criteria that prioritize analytical documentation over naming consistency. Require third-party purity verification, endotoxin testing below 1 EU/mg for in vivo work, and sequence confirmation via both mass spectrometry and amino acid analysis. Accept TB500, TB-500, and Thymosin Beta-4 as interchangeable designations in your inventory system, but reject any supplier who can't provide a COA with these parameters clearly documented. That's the standard we maintain across our full peptide collection. Small-batch synthesis with exact amino-acid sequencing verification for every vial, guaranteeing that what you order is what you receive regardless of how the name is formatted on the procurement form.
- The research peptide industry would benefit from unified nomenclature, but until that happens, responsibility falls on individual researchers to verify molecular identity through analytical data rather than assuming label formatting signals compound differences. TB500 is TB-500. The hyphen is typographic noise. Focus on the chemistry.